Clinuvel Pharmaceuticals Ltd
ASX:CUV
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
|
Walt Disney Co
NYSE:DIS
|
US |
|
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
Clinuvel Pharmaceuticals Ltd
Accounts Payable
Clinuvel Pharmaceuticals Ltd
Accounts Payable Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Accounts Payable | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
Clinuvel Pharmaceuticals Ltd
ASX:CUV
|
Accounts Payable
AU$10.7m
|
CAGR 3-Years
36%
|
CAGR 5-Years
16%
|
CAGR 10-Years
19%
|
|
|
Mesoblast Ltd
ASX:MSB
|
Accounts Payable
$33.6m
|
CAGR 3-Years
13%
|
CAGR 5-Years
3%
|
CAGR 10-Years
3%
|
|
|
CSL Ltd
ASX:CSL
|
Accounts Payable
$3.2B
|
CAGR 3-Years
7%
|
CAGR 5-Years
14%
|
CAGR 10-Years
13%
|
|
|
Race Oncology Ltd
ASX:RAC
|
Accounts Payable
AU$167.8k
|
CAGR 3-Years
-32%
|
CAGR 5-Years
24%
|
CAGR 10-Years
N/A
|
|
|
Telix Pharmaceuticals Ltd
ASX:TLX
|
Accounts Payable
AU$71.7m
|
CAGR 3-Years
62%
|
CAGR 5-Years
65%
|
CAGR 10-Years
N/A
|
|
|
PYC Therapeutics Ltd
ASX:PYC
|
Accounts Payable
AU$9.6m
|
CAGR 3-Years
11%
|
CAGR 5-Years
69%
|
CAGR 10-Years
33%
|
|
Clinuvel Pharmaceuticals Ltd
Glance View
Clinuvel Pharmaceuticals Ltd. operates as a biopharmaceutical company. The company is headquartered in Melbourne, Victoria. The company went IPO on 2001-02-13. The firm is focused on developing and commercializing treatments for patients with genetic, metabolic, and life-threatening disorders, as well as healthcare solutions for the general population. The Company’s principal activity consists of commercializing and distribution in Europe and the United States of its drug candidate SCENESSE for the treatment of a rare, genetic metabolic disorder erythropoietic protoporphyria (EPP). The company is also focused on developing and commercializing SCENESSE as a combination with narrowband ultraviolet B (NB-UVB) phototherapy and topical pharmaceutical formulations of melanocortin analogues for the treatment of the skin depigmentation disorder vitiligo. Its research and development of PRENUMBRA, a new liquid formulation of afamelanotide for the treatment of acute disorders and vascular anomalies.
See Also
What is Clinuvel Pharmaceuticals Ltd's Accounts Payable?
Accounts Payable
10.7m
AUD
Based on the financial report for Dec 31, 2025, Clinuvel Pharmaceuticals Ltd's Accounts Payable amounts to 10.7m AUD.
What is Clinuvel Pharmaceuticals Ltd's Accounts Payable growth rate?
Accounts Payable CAGR 10Y
19%
Over the last year, the Accounts Payable growth was 89%. The average annual Accounts Payable growth rates for Clinuvel Pharmaceuticals Ltd have been 36% over the past three years , 16% over the past five years , and 19% over the past ten years .
